Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2.

John, Mathias; Meyerhof, Wolfgang; Richter, Dietmar; Waser, Beatrice; Schaer, Jean‐Claude; Scherübl, Hans; Boese-Landgraf, J.; Neuhaus, P.; Ziske, Carsten; Molling, K; Riecken, Ernst–Otto; Reubi, Jean Claude; Wiedenmann, Bertram

doi:10.1136/gut.38.1.33

Cited by 104 publications

(72 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, expression of multiple somatostatin receptor subtypes including a high expression of sstr4 and sstr5 was demonstrated in carcinoid tumours. This is at a variance with previous studies, in which only sstr2 could be regularly demonstrated by RT-PCR in scintigraphically positive neuroendocrine tumours (John et al, 1996). One, less likely, explanation for this discrepancy is the difference in methods used to demonstrate sstr subtypes.…”

Section: Somatostatin Receptor Scintigraphy and T/b 1111n Activity Cocontrasting

confidence: 74%

“…Based on binding studies of the cloned receptors, sstr2 has been suggested to be the main target for octreotide and a prerequisite for tumour imaging. This assumption has been supported by studies comparing octreotide scintigraphy with the expression of sstr subtypes in gastroenteropancreatic endocrine tumours (Kubota et al, 1994;John et al, 1996). However, in these studies only small numbers of each tumour type were analysed by reverse transcriptase polymerase chain reaction (RT-PCR) and correlated with octreotide scintigraphy or somatostatin autoradiography.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours

Nilsson

Kölby²,

Wängberg³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

SummaryWe have compared the expression of somatostatin receptor (sstr) subtypes with the outcome of somatostatin receptor scintigraphy and the effect of somatostatin receptor activation in patients with disseminated carcinoid tumours. Tumour tissues from nine patients with midgut carcinoids (ileal) and three patients with foregut carcinoids (gastric, thymic) were analysed using Northern blotting. Expression of somatostatin receptors was demonstrated in all tumours (12 out of 12), with all five receptor subtypes present in 9 out of 12 tumours. Somatostatin receptor scintigraphy using [1111n]DTPA-D-Phe1-octreotide visualized tumours in all patients (12 out of 12). The "'in activity concentrations in tumour tissue (T) and blood (B) were determined in three tumours 1-7 days after injection of the radionuclide. The T/B 1111n activity concentration ratios ranged between 32 and 651. Clinically, treatment with the long-acting somatostatin analogue octreotide resulted in marked symptom relief accompanied by a significant reduction in tumour markers, for example urinary-5-HIAA levels (28-71% reduction).Incubation of midgut carcinoid tumours in primary culture with octreotide (10 gM) resulted in a reduction in spontaneously secreted serotonin (45-71% reduction) and 5-HIAA (41-94% reduction). The results demonstrate that carcinoid tumours possess multiple somatostatin receptor subtypes and that somatostatin analogues such as octreotide, which preferentially bind to somatostatin receptor subtype 2 and 5, can be used in the diagnosis and medical treatment of these tumours. In the future, novel somatostatin analogues with subtype specific receptor profiles may prove to be of value for individualizing the treatment of disseminated carcinoid tumour disease.

show abstract

Section: Somatostatin Receptor Scintigraphy and T/b 1111n Activity Cocontrasting

confidence: 74%

mentioning

confidence: 99%

Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours

Nilsson

Kölby²,

Wängberg³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…The short-term effect on plasma hormone concentrations of a single dose of octreotide in humans is closely correlated with the detection of neuroendocrine tumours with somatostatin receptor scintigraphy (SRS), and with the effectiveness of long-term treatment (Lamberts et al, , 1990John et al, 1996). In a previous study, we demonstrated that octreotide decreased plasma insulin concentrations with a resultant increase in plasma glucose concentrations in eight dogs with insulinoma.…”

Section: Introductionmentioning

confidence: 90%

Effect of octreotide on plasma concentrations of glucose, insulin, glucagon, growth hormone, and cortisol in healthy dogs and dogs with insulinoma

Robben

Brom

Mol

et al. 2006

Research in Veterinary Science

View full text Add to dashboard Cite

The inhibitory effect of the somatostatin analogue octreotide on the secretion of insulin could be used in the treatment of insulinoma. However, current information on the effectiveness of octreotide in dogs is conflicting. Therefore, the endocrine effects of a single subcutaneous dose of 50 lg octreotide were studied in healthy dogs in the fasting state (n = 7) and in dogs with insulinoma (n = 12).Octreotide did not cause any adverse effects. In healthy dogs in the fasting state, both plasma insulin and glucagon concentrations declined significantly. Basal (non-pulse related) GH and ACTH concentrations were not affected. A slight but significant decrease in the plasma glucose concentrations occurred.Dogs with insulinoma had significantly higher baseline insulin concentrations and lower baseline glucose concentrations than healthy dogs in the fasting state. Plasma glucagon, GH, ACTH, and cortisol concentrations did not differ from those in healthy dogs. Baseline plasma insulin concentrations decreased significantly in dogs with insulinoma after octreotide administration, whereas plasma concentrations of glucagon, GH, ACTH, and cortisol did not change. In contrast to the effects in the healthy dogs, in the dogs with insulinoma plasma glucose concentrations increased.Thus, the consistent suppression of plasma insulin concentrations in dogs with insulinoma, in the absence of an suppressive effect on counter-regulatory hormones, suggests that further studies on the effectiveness of slow-release preparations in the long-term medical treatment of dogs with insulinoma are warranted.

show abstract

“…There are 5 predominant subtypes of SSTR, type 2 being the most commonly expressed in NETs (3). Somatostatin analogs (SSAs) such as octreotide and lanreotide exert their therapeutic effects by activating SSTRs, which slow tumor growth and inhibit tumorassociated hormone secretion.…”

Section: Sstrmentioning

confidence: 99%

Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors

et al. 2017

View full text Add to dashboard Cite

Somatostatin receptor (SSTR) PET has demonstrated a significant improvement over conventional imaging (CI) in patients with neuroendocrine tumors (NETs). SSTR PET should replace 111 In-pentetreotide scintigraphy (OctreoScan; Mallinckrodt) in all indications in which the latter is currently being used. These appropriate use criteria (AUC) are intended to aid referring medical practitioners in the appropriate use of SSTR PET for imaging of patients with NETs. The indications were evaluated in welldifferentiated NETs. Of the 12 clinical scenarios evaluated, 9 were graded as appropriate: initial staging after the histologic diagnosis of NET, evaluation of an unknown primary, evaluation of a mass suggestive of NET not amenable to endoscopic or percutaneous biopsy, staging of NET before planned surgery, monitoring of NET seen predominantly on SSTR PET, evaluation of patients with biochemical evidence and symptoms of a NET, evaluation of patients with biochemical evidence of a NET without evidence on CI or a prior histologic diagnosis, restaging at time of clinical or laboratory progression without progression on CI, and new indeterminate lesion on CI with unclear progression.

show abstract

Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2.

Cited by 104 publications

References 28 publications

Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours

Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours

Effect of octreotide on plasma concentrations of glucose, insulin, glucagon, growth hormone, and cortisol in healthy dogs and dogs with insulinoma

Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors

Contact Info

Product

Resources

About